ACHN News 7.00 08/08/2014 04:23:55 Achillion Pharmaceuticals

New Post Public Reply Private Reply Replies (0) Message Board

Aug 8, 2014 at 5:23 AM

Achillion Pharmaceuticals (ACHN) 7.00 $ACHN

Achillion Reports Second Quarter and Six Month 2014 Financial Results
GlobeNewswire - Thu Aug 07, 3:44PM CDT
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today reported financial results for the three and six months ended June 30, 2014 and provided an update on the Company's portfolio of clinical stage compounds being developed for the treatment of the hepatitis C virus (HCV).

Critical Alerts For Achillion Pharmaceuticals, Synergy Resources, Invensense, JinkoSolar, and Harley-Davidson Released By InvestorsObserver
PR Newswire - Tue Aug 05, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for ACHN, SYRG, INVN, JKS, and HOG.

Critical Alerts For Exelixis, Rocket Fuel, Netflix, Johnson & Johnson, and Achillion Pharmaceuticals Released By InvestorsObserver
PR Newswire - Tue Jul 15, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for EXEL, FUEL, NFLX, JNJ, and ACHN.

Why American Apparel, Glu Mobile, and Achillion Pharmaceuticals Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Fri Jul 11, 4:15PM CDT
We haven't been able to say this often recently, but the broad-based S&P 500 limped into Friday's close with a modest gain, but still finished the week lower by nearly 1%. As is typical with most Fridays, economic data was fairly light....

Nasdaq stocks posting largest percentage increases
AP - Fri Jul 11, 12:38PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:

Technical Data on Health Care Sector Equities -- Research on Achillion Pharma, Novavax, Dendreon, and Exelixis
PR Newswire - Thu Jul 10, 6:00AM CDT
On Wednesday, July 09, 2014, the NASDAQ Composite ended at 4,419.03, up 0.63%, the Dow Jones Industrial Average advanced 0.47%, to finish the day at 16,985.61, and the S&P 500 closed at 1,972.83, up 0.46%. The gains were broad based with nine out of ten sectors ending the session in positive. The S&P 500 Health Care Sector Index ended the day at 712.05, up 0.38%, with the index advancing 5.76% in the previous three months. Investor-Edge has initiated coverage on the following equities: Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Novavax Inc. (NASDAQ: NVAX), Dendreon Corp. (NASDAQ: DNDN) and Exelixis Inc. (NASDAQ: EXEL). Free technical research on ACHN, NVAX, DNDN and EXEL can be downloaded upon signing up at:

Agreements, NDA Submissions, FDA Approvals, Enrollment Updates, and Index Inclusions - Analyst Notes on Jazz Pharmaceuticals, Vertex, NPS, StemCells and Achillion
PR Newswire - Mon Jul 07, 4:50AM CDT
Today, Analysts Review released its analysts' notes regarding Jazz Pharmaceuticals plc (NASDAQ: JAZZ), Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), StemCells, Inc. (NASDAQ: STEM) and Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4482-100free.

The 5 Best Healthcare Stocks so Far in 2014
Todd Campbell, The Motley Fool - Motley Fool - Sun Jul 06, 8:30AM CDT
Healthcare stocks put up impressive returns last year and are trumping the S&P 500 yet again this year. The S&P health care select index ETF (XLV) is up more than 10% this year and the iShares Nasdaq biotechnology ETF (IBB) has gained...

Achillion Pharmaceuticals Added to the Russell 2000 and Russell Microcap Indexes
GlobeNewswire - Tue Jul 01, 3:05PM CDT
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced that it has been added to the Russell 2000 and Russell Microcap Indexes. Each June, Russell realigns its family of global equity indexes to reflect market changes in the past year.

3 Stocks With Eye-Popping Gains This Month
Todd Campbell, The Motley Fool - Motley Fool - Mon Jun 30, 2:12PM CDT
Shares in biotechnology companies can make breathtaking moves higher and lower on whims and whispers, and June was no exception. Following the sector's rollicking ride higher last year and dramatic sell-off in the first quarter, investors are right...

Achillion
at Investor's Business Daily - Fri Jun 20, 5:38PM CDT
Achillion (ACHN) shares rose 0.6% to 8.13 after R. W. Baird noted that Merck's (MRK) official tender offer indicated that there was another bidder for Idenix Pharmaceuticals, which means that a company is still looking for a nucleoside hepatitis C...

Achillion Could Win Idenix's Mystery Suitor: Analyst
at Investor's Business Daily - Fri Jun 20, 11:44AM CDT
Hot biotech stock Achillion Pharmaceuticals (ACHN) was up 2%, near 8.20, in midday trading in the stock market today after an analyst found more support for its prospects as a buyout candidate. R. W. Baird's Brian Skorney noted that Merck's (MRK)...

The Zacks Analyst Blog Highlights: Idenix, Achillion Pharmaceuticals, Nektar, Orexigen, Celgene, Alexion and Biogen
PR Newswire - Thu Jun 19, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Idenix (Nasdaq:IDIX-Free Report), Achillion Pharmaceuticals (Nasdaq:ACHN-Free Report), Nektar (Nasdaq:NKTR-Free Report), Orexigen (Nasdaq:OREX-Free Report), Celgene (Nasdaq:CELG-Free Report), Alexion (Nasdaq:ALXN-Free Report) and Biogen (Nasdaq:BIIB-Free Report).

Biotech Stock Roundup: HCV Back in Focus - Idenix, Achillion Soar - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jun 18, 9:33AM CDT
It was about hepatitis C cirus (HCV) treatments and companies last week with the Merck-Idenix acquisition announcement grabbing eyeballs.

Nasdaq stocks posting largest volume increases
AP - Tue Jun 17, 5:03PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:

Most active Nasdaq-traded stocks
AP - Tue Jun 17, 5:03PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Hugel's Sales Climb Despite Changes in Sales Models

Hugel's Financial Fortunes in a Shifting Landscape Who would've thought? That’s the vibe hugging the numbers Hugel Inc. just dropped. Their performance for the first three quarters of 2026 is in the books, and results show consolidated net sales climbing 15% year-on-year. Just how did they pull this rabbit out of the hat? Let's dissect this a bit. Cracking the Code of...

Are BWIN, LFCR, PCRX Shareholder Deals Fair?

What's Really Going On with BWIN, LFCR, and PCRX? Everyone talks about when there's smoke, there's fire. But in this case, it’s hard not to wonder if we're standing knee-deep in burning embers, or just a dusty old campfire. Halper Sadeh LLC is ringing the alarm bells for Baldwin Group, Lifecore Biomedical, and Pacira BioSciences, the trio tagged under NASDAQ: BWIN,...

MRP Securities Fraud: Investors Eye Millrose Case

Millrose's Troubles: A Closer Look at the Fraud Accusation Now, here's a pickle. Millrose Properties, Inc. (NYSE: MRP) has landed itself in hot water. We've got a bona fide class action lawsuit on our hands, and Schall, Brown & Schwartz LLP is waving the flag, rallying investors to step up and face the music. Turns out the company's talk might not have walked the walk...

Peabody's Q3 2026: Margins Climb Despite Net Loss

Tough Quarters but Promising Margins Alright, Peabody's Q3 2026 isn't the most sunshine-filled report I've laid eyes on, but it's not all shadows either. Sure, they posted a net loss of $32.8 million, better than last year's $70.1 million drain. Admit it or not, that's improvement. And yet, the real gem here is those expanding margins gleaming despite the loss-heavy...

Omnissa Expands AI Sovereignty: New Markets, New Control

Omnissa Rolls Out AI Sovereignty Across New Markets In the world of AI, where data is king and control is the crown, Omnissa is making bold moves with its latest expansion announcement. The company's Sovereign Solution (OSS) is now reaching into six fresh markets across Europe and Asia, offering organizations a vital grip on their digital domains like never before. Talk...

UN Forum Unleashes LatAm CEO Coalition for Action

Latin America Takes Center Stage When the UN turns its spotlight on a region, you know there's something afoot. Right in Montevideo, Uruguay, the United Nations Global Compact gathered a hefty crowd of over 300 leaders from diverse backgrounds—think business, finance, government, and academia. What they were brewing wasn’t just talk; it was about driving real change...

Lincoln Index Highlights Growth, But Risks Linger

Private Market Dynamics: A Mixed Bag in Q3 The Lincoln Private Market Index (LPMI) is giving us quite the mixed message this quarter. Up by 2.8%, the index is applauding earnings growth in private companies. Not too shabby, right? Yet, let's not pop the champagne just yet. It's not all sunshine and roses—credit risk clouds are looming large. Steady Performers, but Not...

Lumentum Holders Question Marvell Deal Fairness: Legal Eyes

What's Brewing with Lumentum and Marvell? There's no denying the chatter on Wall Street when there's a potential shake-up, especially with a big merger at stake. We're staring down the barrel of an investigation concerning Lumentum Holdings Inc. (NASDAQ: LITE) and Marvell Technology, Inc.'s deal. The M&A Class Action Firm, helmed by Juan Monteverde, is the name leading...

Fluence Energy Faces Legal Trouble: A Closer Look

Fluence Energy's Legal Tangle: What It Means for Investors You ever get that gut punch feeling when a company you’re watching stumbles? Well, Fluence Energy, Inc. (NASDAQ: FLNC) seems to have handed that to its shareholders lately. There's a class action lawsuit out there that’s got investors not only scratching their heads but also reaching for their phones. The...

EXPO 2027 Belgrade: Serbia's Tourism Game-Changer?

An Unexpected Stage: Belgrade's Big Show Well, who's betting on Belgrade making waves in the global travel scene? EXPO 2027 is shaping up to do just that, and it’s taking the scenic route. Serbia, a country not always on the grand tourist itineraries, could finally hog the spotlight come 2027. Under the banner of 'Play for Humanity: Sport and Music for All,' they're...